ContraFect (CFRX) Receives $2.1M PRMRP-Related Development Award

November 17, 2016 7:18 AM EST
Get Alerts CFRX Hot Sheet
Trade CFRX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

ContraFect Corporation (Nasdaq: CFRX) (Nasdaq: CFRXW) announced that it has been granted a $2.1 million Technology/Therapeutic Development Award through the US Department of Defense Peer Reviewed Medical Research Program (PRMRP).

The Technology/Therapeutic Development Award is designed to support diagnostics or therapies that have the potential to make a strong impact on patient care. The award is granted after a peer-review process and will support the development of ContraFect's principal therapeutic candidate, CF-301, a first-in-class lysin which is active against Staphylococcus aureus (Staph aureus) bacteria.

"We are pleased to receive this award which will support additional research on CF-301 for the current development program in Staph aureus bacteremia and endocarditis, as well as potential future indications," said Steven C. Gilman, PhD, Chairman and CEO of ContraFect.

About CF-301:

CF-301 is a recombinant bacteriophage-derived lysin with potent bactericidal activity against Staph aureus, a major cause of bloodstream infections, or bacteremia. CF-301 has the potential to be a first-in-class treatment for Staph aureus bacteremia. It has a novel, rapid, and specific mechanism of bactericidal action against Staph aureus and does not impact the body's natural bacterial flora. By targeting a conserved region of the cell wall that is vital to bacteria, resistance is less likely to develop to CF-301. Combinations of CF-301 with standard of care antibiotics significantly increased bacterial killing and survival in animal models of disease when compared to treatment with antibiotics or CF-301 alone. In addition, in vitro and in vivo experiments have shown that CF-301 is highly active against biofilm infections. CF-301 was licensed from The Rockefeller University and is being developed at ContraFect. CF-301 is the first lysin to enter clinical trials in the U.S.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Management Comments

Add Your Comment